Polaryx Therapeutics, Inc. has appointed Dr. Will Charlton Chief Medical Officer, effective September 1, 2026, as the company prepares to launch its SOTERIA Phase 2 basket trial for PLX-200. CEO Alex Yang said Charlton’s “extensive experience serving as a Chief Medical Officer and leading rare disease clinical trials, coupled with his background as a pediatrician and passion for developing patient-friendly therapies,” make him “an excellent fit to lead our SOTERIA trial.”
About Dr. Will Charlton
Yang said that with SOTERIA on track to initiate in the fourth quarter of 2026, Charlton’s “proven track record will be highly valuable as we execute the trial, advance key clinical milestones, and deepen our engagement with the patients and families affected by lysosomal storage disorders.” Charlton said he was “excited to join Polaryx at such an important stage of the company’s clinical development,” adding that he was “impressed by the extensive preclinical work and established safety profile supporting PLX-200,” and that he looks forward to “bringing my experience to the SOTERIA trial and being of service to pediatric patients and families.”
A board-certified pediatric endocrinologist with nearly two decades of leadership experience, Charlton joins Polaryx from Tyra Biosciences, where he served as Senior Vice President of Clinical Development, directing Phase 2 rare disease trials in skeletal dysplasia. Before that, he was Chief Medical Officer at Spruce Biosciences, where he led clinical strategy for treatments targeting congenital adrenal hyperplasia. Earlier in his career, Charlton held senior medical director and clinical development roles at 89bio, Ascendis Pharma, and Allergan, and spent more than a decade in pediatric endocrinology clinical practice.
Charlton earned his medical degree from the University of Southern California’s Keck School of Medicine, completed his pediatric internship and residency at Children’s Hospital Los Angeles, and completed a fellowship in pediatric endocrinology along with a Master of Advanced Studies in Clinical Research at the University of California, San Francisco. He holds a Bachelor of Arts in Liberal Studies from the University of the Pacific and is licensed by the Medical Board of California.
About Polaryx Therapeutics
Polaryx Therapeutics is a clinical-stage biotechnology company, founded in 2014, developing patient-friendly small molecule and gene therapy treatments for rare, orphan lysosomal storage disorders. Its lead candidate, PLX-200, has received FDA Fast Track designation for all four indications to be evaluated in the company’s SOTERIA trial: CLN2 disease, CLN3 disease, Krabbe disease, and Sandhoff disease. SOTERIA is a Phase 2, open-label, single-arm basket trial designed to assess the safety, tolerability, and clinical activity of PLX-200 across all four conditions, with sites planned across the United States, Europe, and Asia.
